NCT05737628Not yet recruiting
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 Alone and in Combination With Rituximab to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Relapsed/Refractory CD20 Positive B-cell Non-Hodgkin's Lymphoma (NHL)
Byondis B.V.Phase 1ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Lymphoma
- Drug/Device/Intervention
- BYON4228 + Rituximab
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Byondis B.V.
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Apr 01, 2023
- End date
- Dec 01, 2025
- Enrollment
- 100 participants
Primary outcome
Incidence of dose-limiting toxicities
Summary
This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb)
 directed against SIRPα.
ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05737628
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05737628 through Pure Global AI's free database. This Phase 1 trial is sponsored by Byondis B.V. and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.